are common in other fungi); and plants have unsaturated bases such as sphing-8-enines, sphing-4,8-dienes and phytosphing-(8 or 9)-enines.
Some organisms (such as fungi and sponges) produce compounds that are sphingoid base-like, as illustrated in Fig. 2 . The compounds shown lack the 1-hydroxyl group present in sphingoid bases and have threo stereochemistry for the vicinal amine and hydroxyl. As will be discussed later, at least some of these disrupt sphingolipid metabolism.
De novo sphingolipid biosynthesis
The capacity for de novo sphingolipid biosynthesis ( Fig. 1 ) is widespread among cell types and tissues, and in the absence of an exogenous source of sphingoid bases, loss of this pathway (by mutation of serine palmitoyltransferase, SPT, in mammalian cells in culture and yeast) (8, 9) affects growth and viability. In addition, inhibition of SPT (by ISP1/myriocin and sphingofungin B) is growth inhibitory and cytotoxic unless the cells are rescued by giving sphingosine (10) .
These findings have important implications in vivo because, although sphingolipids are present in most foods, the sphingoid bases are largely degraded in the mammalian intestine (11); hence, de novo sphingolipid biosynthesis appears to be necessary. Figure 1 displays the enzymes, intermediates and products known to participate in sphingoid base biosynthesis de novo. It is intriguing that this pathway contains so many compounds that affect cell behavior when added exogenously: sphingoid bases are highly cytotoxic (12) , perhaps through targets such as a sphingosine-activated 14-3-3 kinase (13), inhibition of phosphatidic acid phosphatase (14) and protein kinase C (15) , and probably other mechanisms; ceramides (but much less so dihydroceramides) induce growth arrest and programmed cell death through targets such as protein kinases and phosphoprotein phosphatases (1); and, sphingoid base 1-phosphates are mitogenic and can inhibit apoptosis via intracellular and extracellular receptors (2) . With so many bioactive intermediates, efficient coordination of essentially all of the enzymes of sphingolipid metabolism must be maintained, with three of the enzymes warranting particular attention being: serine palmitoyltransferase, as the enzyme that catalyzes the initial step of the pathway; (dihydro)ceramide synthase, as the enzyme that removes sphingoid bases as well as produces dihydroceramide (or ceramide, if sphingosine is available from sphingolipid turnover or an exogenous source); and dihydroceramide desaturase, which inserts the 4-trans-double bond that converts dihydroceramides from a relatively inactive signaling species to the ceramides, which can induce diverse cell responses, including growth arrest and apoptosis (1).
Serine palmitoyltransferase (SPT).
For mammals and yeast, two gene products (termed SPTLC1 and SPTLC2, or sometimes SPT1 and SPT2) are necessary for this activity (15) and appear to be physically associated (16) . A third has also been identified in yeast, but does not appear to have a homolog in mammals (17 The regulation of SPT activity and its role in controlling de novo sphingolipid synthesis are only beginning to be understood. One of the more straightforward factors that affects SPT activity is the availability of its substrates because cellular concentrations of serine vary over the same range as the Km for serine determined both in vitro and in intact cells (24) . Sphingoid base biosynthesis is also affected by the availability of palmitic acid (24) , for which mammalian SPT is highly selective (preferring fatty acyl-CoA with 16 + 1 carbon atoms); other fatty acids can be inhibitory, possibly by reducing palmitoyl-CoA due to competition for the
CoA pool (24).
Serine palmitoyltransferase is inhibited by a number of synthetic and naturally occurring agents. As for many pyridoxal 5'-phosphate dependent enzymes, it undergoes active-site dependent ("suicide") inhibition with β-haloalanines and other aldehyde reactive compounds such as cycloserine (26, 27) .
More potent and selective inhibitors have been isolated from microorganisms (sphingofungins, lipoxamycins, and ISP1/myriocin) ( Based on studies of the deuterium isotope effects on C-H bond cleavage, the mammalian dihydroceramide (∆4) desaturase initially oxidizes C-4 (52), which is consistent with the finding of a single enzymatic system that catalyzes both ceramide and phytoceramide synthesis (51) . A cyclopropene analog of ceramide has been shown to inhibit the desaturase at micromolar concentrations (53).
The genes responsible for synthesis of phytosphingosine have been identified in yeast (54, 55) , plants (56) and M. musculus (51) . In vitro assays suggest that the hydroxylation of sphinganine to form phytosphingosine can occur with both the free sphingoid base and dihydroceramide, at least in yeast (55), as depicted by the dashed arrow in Fig. 1 .
Other reactions. The enzymes that remove ceramide (both ceramidases and synthases for complex sphingolipids) and kinase(s) that metabolize sphingoid bases to the 1-phosphates (as well as the phosphatases that reverse this reaction and the lyase that cleaves sphingoid base 1-phosphates to a fatty aldehyde and ethanolamine phosphate) also impact this pathway (Fig. 1) ; these will be discussed in the accompanying minireviews (1,2).
Implication of de novo sphingolipid biosynthesis in cell death
The first demonstration of toxicity due to alteration of de novo sphingolipid biosynthesis was that inhibition of (dihydro)ceramide synthase is responsible for much, if not all, of the toxicity of fumonisins (44, 57) . Fumonisins are mycotoxins in corn and a number of other foods that cause of equine leukoencephalomalacia and porcine pulmonary edema, and have been implicated in human cancer and other disease (58) . By inhibiting (dihydro)ceramide synthase, fumonisins block the formation of complex sphingolipids and cause accumulation of sphinganine (Fig. 3) , which can be released into circulation and affect other tissues. Elevated sphinganine in serum and urine are also widely used as a biomarker of fumonisin exposure (59, 60) . The accumulation of sphinganine appears to be responsible for most of the deleterious effects of these mycotoxins, although depletion of complex sphingolipids impairs the function of some membrane proteins, such as the folate transporter (61), and may contribute to the pathology.
Fumonisins can significantly elevate sphinganine 1-phosphate (62) and production of ethanolamine phosphate (63) ( Fig. 1 and 3 agents such as angiotensin II and cannabinoids (66, 67) , and elevations in palmitoylCoA due to excess production or impaired removal by mitochondrial oxidation or other metabolism (68) (Fig. 3) . This has implications for a wide range of disorders, and has been articulated as one of the mechanisms for "lipotoxic" disease (69).
Perspectives
It is not clear why nature would "risk" producing intermediates in a biosynthetic pathway with such a diverse spectrum of biological effects and toxicities unless they have functions beyond just being steps toward endproducts. Thus, one suspects that the toxicity of compounds such as the fumonisins reflects severe disruption of a sphingolipid biomonitor that cells utilize for more subtle regulatory purposes. And, as often occurs in nature, pathogenic organisms have developed ways to exploit these pathways for their own purposes; in the case of the fumonisins, to allow the fungus to kill its host (maize).
Some of the advantages of forming highly bioactive compounds via both complex sphingolipid turnover and de novo biosynthesis are: 1) the amounts of the backbones (sphingoid bases and ceramides) can be raised to higher levels than by sphingolipid turnover alone since palmitoyl-CoA and serine are plentiful; 2) the bioactive sphingolipid backbone(s) can be formed with minimal perturbation of the cellular status/utilization of complex sphingolipids; 3) the bioactive compounds may be targeted more directly to the intracellular membranes where they are needed; 4) the formation and removal of these species could be integrated with other cell states, such as whether or not the mitochondria are active and utilizing palmitoyl-CoA (Fig. 3) ; and, 5) the molecular subspecies (such as the type of fatty acid on the ceramide) can be modified to activate/inhibit downstream targets more selectively.
Whether one is studying de novo sphingolipid biosynthesis under normal or abnormal conditions, it should be evident that this necessitates examination of all of these bioactive species as well as when and where they are made and removed (70) .
This will require comprehensive, "-omic" technologies ("sphingolipidomics"), which certainly would have pleased Thudichum (5) (72) were both isolated as bioactive compounds from sponges. Merrill, Figure 3 by guest on September 27, 2016 
